CTAD 2023: Grifols/Araclon Ponder Next Steps For ABvac40 After Phase II Readout

Ongoing Mid-Stage Data Analysis Will Inform Trial Plans

 
• By Mandy Jackson
  
Abstract blue brain. Brain anatomy.
Brain atrophy was not as pronounced in ABvac40-treated patients • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D